Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 4:13:866582.
doi: 10.3389/fimmu.2022.866582. eCollection 2022.

AIOLOS Variants Causing Immunodeficiency in Human and Mice

Affiliations
Review

AIOLOS Variants Causing Immunodeficiency in Human and Mice

Motoi Yamashita et al. Front Immunol. .

Abstract

AIOLOS is encoded by IKZF3 and is a member of the IKAROS zinc finger transcription factor family. Heterozygous missense variants in the second zinc finger of AIOLOS have recently been reported to be found in the families of patients with inborn errors of immunity. The AIOLOSG159R variant was identified in patients with B-lymphopenia and familial Epstein-Barr virus-associated lymphoma. Early B-cell progenitors were significantly reduced in the bone marrow of patients with AIOLOSG159R. Another variant, AIOLOSN160S was identified in the patients presented with hypogammaglobulinemia, susceptibility to Pneumocystis jirovecii pneumonia, and chronic lymphocytic leukemia. Patients with AIOLOSN160S had mostly normal B cell counts but showed increased levels of CD21lo B cells, decreased CD23 expression, and abrogated CD40 response. Both variants were determined to be loss-of-function. Mouse models harboring the corresponding patient's variants recapitulated the phenotypes of the patients. AIOLOS is therefore a novel disease-causing gene in human adaptive immune deficiency.

Keywords: AIOLOS; IKAROS; IKZF transcription factor; IKZF3; inborn errors of immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with the authors MY and TM.

Figures

Figure 1
Figure 1
IKZF protein structures. (A) DNA-binding zinc fingers (ZF1–4) and dimerizing zinc fingers (ZF5–6) are represented by light green and yellow boxes, respectively. The colored lines represent the germline variants reported in IEIs (IKAROS, HELIOS, and AIOLOS) and hereditary thrombocytopenia (PEGASUS). The exon junctions are indicated with dashed lines. (B) Amino acid sequences of the ZF2 of IKAROS and AIOLOS are presented. The numbers indicate the positions of amino acids, whereas red letters represent the amino acids interacting with zinc ions. Above, the secondary structures of ZF2 are shown with the numbers represent amino acid positions in reference to the beginning of α helix. Missense variants of amino acids with purple background are known to be the causes of IKAROS deficiency. Missense variants of G159 (light green background) and N160 (pink background) are known to cause immunodeficiency. The arginine substitution of L162 (yellow background) is known as the hotspot somatic mutation in CLL.
Figure 2
Figure 2
Summary of patients, murine models, and in vitro studies of AIOLOS variants. Circles indicate the patients who presented with the indicated phenotypes. Each column of the circle represents each patient, sorted by the age of the patients. Pedigrees of the study patients are presented above. Two patients with AIOLOSG159R had died at the time of the study. The phenotypes of both heterozygous (Het) and homozygous (Homo) mice were presented. EBV, Epstein–Barr virus; CLL, chronic lymphocytic leukemia; FO, follicular; MZ, marginal zone; TCR, T-cell receptor; EMSA, electrophoretic mobility shift assay; DN, dominant-negative; PC-HC, pericentromeric heterochromatin foci formation assay; LOF, loss-of-function.

References

    1. Morgan B, Sun L, Avitahl N, Andrikopoulos K, Ikeda T, Gonzales E, et al. . Aiolos, a Lymphoid Restricted Transcription Factor That Interacts With Ikaros to Regulate Lymphocyte Differentiation. EMBO J (1997) 16:2004–13. doi: 10.1093/emboj/16.8.2004 - DOI - PMC - PubMed
    1. Wang J-H, Avitahl N, Cariappa A, Friedrich C, Ikeda T, Renold A, et al. . Aiolos Regulates B Cell Activation and Maturation to Effector State. Immunity (1998) 9:543–53. doi: 10.1016/s1074-7613(00)80637-8 - DOI - PubMed
    1. Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, et al. . Aiolos Promotes TH17 Differentiation by Directly Silencing Il2 Expression. Nat Immunol (2012) 13:770–7. doi: 10.1038/ni.2363 - DOI - PMC - PubMed
    1. Holmes ML, Huntington ND, Thong RP, Brady J, Hayakawa Y, Andoniou CE, et al. . Peripheral Natural Killer Cell Maturation Depends on the Transcription Factor Aiolos. EMBO J (2014) 33:2721–34. doi: 10.15252/embj.201487900 - DOI - PMC - PubMed
    1. Thompson EC, Cobb BS, Sabbattini P, Meixlsperger S, Parelho V, Liberg D, et al. . Ikaros DNA-Binding Proteins as Integral Components of B Cell Developmental-Stage-Specific Regulatory Circuits. Immunity (2007) 26:335–44. doi: 10.1016/j.immuni.2007.02.010 - DOI - PubMed

Publication types

MeSH terms